 CAMBRIDGE, Mass.--BUSINESS WIRE--Gemini Therapeutics, Inc. Nasdaq: GMTX, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration AMD and linked ocular disorders, today announced the presentation of preclinical data at the 2021 Association for Research in Vision and Ophthalmology ARVO Virtual Annual Meeting, held May 1 to 7, 2021. The poster, titled Anti-angiogenic activity of Complement Factor H in a laser-in 